Filtered By:
Specialty: Drugs & Pharmacology
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 120827 results found since Jan 2013.
Review of the impact of the FDA's Fast Track Designation on biotechnology companies' share prices
This study examines the effect of the FDA's Fast Track Designation (FTD) on biotech company share prices. Using an event-study approach on 25 FTD announcements between June 2019 and June 2020, notable short- and long-term share price hikes were observed, with a 5-day cumulative average abnormal returns of 21.59%, 30-day at 38.34%, 1-year at 76.64% and 3-year at 111.37% against the XBI benchmark. These surges surpass prior research findings, indicating stronger investor reactions. The role of the COVID-19 pandemic as a confounder is discussed. Although the sample size is limited, the results offer valuable insights for inve...
Source: Drug Discovery Today - September 16, 2023 Category: Drugs & Pharmacology Authors: Joab Williamson Alexander James Spicer Source Type: research
Enthesitis in Spondyloarthritis Including Psoriatic Arthritis-To Inject or Not To Inject?: A Narrative Review
Clin Ther. 2023 Sep 14:S0149-2918(23)00303-X. doi: 10.1016/j.clinthera.2023.08.002. Online ahead of print.ABSTRACTPURPOSE: Enthesitis is a key manifestation of psoriatic arthritis (PsA) and spondyloarthritis (SpA) and is considered to be the tissue where the disease initiates. Enthesitis leads to pain and substantial limitations in patients with PsA. Treatment is key in achieving remission or minimal disease activity. Whether it is safe to apply injections to entheseal tissue is unknown. This narrative review aimed to summarize the literature on the efficacy and tolerability of entheseal corticosteroid (CS) injections.METH...
Source: Clinical Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Ozun Bayindir Tsechelidis Ricardo Sabido-Sauri Sibel Zehra Aydin Source Type: research
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.METHODS: This critical review evaluated how recent publications and ongoing clinical trials in atherosclerotic inflammation will affect clinical care.FINDINGS: Key trials, including CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) with canakinumab (interleukin-1β inhibition), and COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low Dose Colchicine 2) with colchicine, have shown that suppressing inflammation can improve outcomes in ASCV...
Source: Clinical Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: N Mohammadnia T S J Opstal S El Messaoudi W A Bax J H Cornel Source Type: research
Restoring prefrontal cortical excitation-inhibition balance with cannabidiol ameliorates neurobehavioral abnormalities in a mouse model of neurodevelopmental disorders
Neuropharmacology. 2023 Sep 14:109715. doi: 10.1016/j.neuropharm.2023.109715. Online ahead of print.ABSTRACTMaternal immune activation (MIA) resulting from viral infections during pregnancy is linked to increased rates of neurodevelopmental disorders in offspring. However, the mechanisms underlying MIA-induced neurobehavioral abnormalities remain unclear. Here, we used a poly (I:C)-induced MIA mouse model to demonstrate the presence of multiple behavioral deficits in male offspring. Through RNA sequencing (RNA-seq), we identified significant upregulation of genes involved in axonogenesis, synaptogenesis, and glutamatergic ...
Source: Neuropharmacology - September 16, 2023 Category: Drugs & Pharmacology Authors: Lu Zhang Chunqiao Lin Jiushuang Zhu Yan He Meng Zhan Xiuwen Xia Ni Yang Kun Yang Baojia Wang Zhanqion Zhong Yili Wang Weijun Ding Youjun Yang Source Type: research
Translated article Medication reconciliation in pediatric hemato-oncologic patients: A multicenter study
CONCLUSIONS: In order to avoid or reduce errors in one of the critical safety points such as transitions of care, there are measures such as medication reconciliation. In the case of complex chronic pediatric patients, such as onco-hematological patients, the number of drugs as part of home treatment is the variable that has been associated with the presence of medication reconciliation errors on admission to hospital, and the omission of some medication was the main cause of these errors.PMID:37716875 | DOI:10.1016/j.farma.2023.07.012
Source: Farmacia Hospitalaria - September 16, 2023 Category: Drugs & Pharmacology Authors: Margarita Cuervas-Mons Vendrell Dolores Pilar Iturgoyen Fuentes Miquel Villaronga Flaque Maria Jos é Cabañas Poy Cecilia M Fern ández-Llamazares Concha Álvarez Del Vayo Carmen Gallego Fern ández Cristina Mart ínez Roca Yolanda Hern ández Gago Ana G Source Type: research
Telocytes protect against lung tissue fibrosis through hexokinase 2-dependent pathway by secreting hepatocyte growth factor
In conclusion, TCs can protect against lung tissue fibrosis by releasing HGF, a process dependent on HK2.PMID:37715611 | DOI:10.1111/1440-1681.13823
Source: Clinical and Experimental Pharmacology and Physiology - September 16, 2023 Category: Drugs & Pharmacology Authors: Shaoyuan Zhang Linyi Sun Borong Chen Siyun Lin Jianmin Gu Lijie Tan Miao Lin Source Type: research
Clinician Response to Pharmacogenetic Clinical Decision Support Alerts
The objective of this study was to characterize clinician response following standardization of pharmacogenetic (PGx) clinical decision support alerts at University of Florida (UF) Health. A retrospective analysis of all PGx alerts that fired at a tertiary academic medical center from August 2020 through May 2022 was performed. Alert acceptance rate was calculated and compared across six gene-drug pairs, patient care setting, and clinician specialty. The disposition of the triggering medication was compared to the alert response and evaluated for congruence. There were a total of 818 alerts included for analysis of alert r...
Source: Clinical Pharmacology and Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Lauren K Lemke Emily J Cicali Roy Williams Khoa A Nguyen Larisa H Cavallari Kristin Wiisanen Source Type: research
Ethical Requirements for Human Challenge Studies: A Systematic Review of Reasons
Clin Pharmacol Ther. 2023 Sep 16. doi: 10.1002/cpt.3054. Online ahead of print.ABSTRACTHuman challenge studies (HCS) are controlled clinical trials in which participants are deliberately infected with a pathogen. Such trials are being developed for an increasing number of diseases. Partly as a result of the COVID-19 pandemic, there has been a recent ethical debate about the reasons for and against HCS in general, or rather, about the requirements that individual HCS must fulfill to be ethically acceptable. A systematic review was conducted to categorize and summarize such requirements and the reasons given for them. Ethics...
Source: Clinical Pharmacology and Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Matthias Katzer Sabine Salloch Christoph Schindler Marcel Mertz Source Type: research
Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation & amp; Quality (IQ) Consortium Perspective on Use Cases and Best Practices
Clin Pharmacol Ther. 2023 Sep 16. doi: 10.1002/cpt.3053. Online ahead of print.ABSTRACTRecent breakthroughs in Artificial Intelligence (AI) and Machine Learning (ML) have ushered in a new era of possibilities across various scientific domains. One area where these advancements hold significant promise is model-informed drug discovery and development (MID3). To foster a wider adoption and acceptance of these advanced algorithms, the Innovation & Quality (IQ) Consortium initiated the AI/ML working group (WG) in 2021 with the aim of promoting their acceptance among the broader scientific community as well as by regulatory...
Source: Clinical Pharmacology and Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Nadia Terranova Didier Renard Mohamed H Shahin Sujatha Menon Youfang Cao Cornelis E C A Hop Sean Hayes Kumpal Madrasi Sven Stodtmann Thomas Tensfeldt Pavan Vaddady Nicholas Ellinwood James Lu Source Type: research
Investigating the heat sensitivity of frequently used excipients with varying particle sizes
Eur J Pharm Biopharm. 2023 Sep 14:S0939-6411(23)00243-6. doi: 10.1016/j.ejpb.2023.09.010. Online ahead of print.ABSTRACTDuring tablet manufacturing an increase in the production temperature can lead to an alteration of tablet characteristics. In the present study, the influence of the initial particle size on the tableting behavior of ductile polymers upon temperature rise was investigated. Different grades of the respective materials were tableted at temperatures ranging from 22-70 °C. Alterations in tableting behavior were affected by the initial particle size. Smaller particle sizes led to a more pronounced decrease in...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Hanna Dorothea Grumann Peter Kleinebudde Source Type: research
The role of macrophages in polycystic ovarian syndrome and its typical pathological features: A narrative review
Biomed Pharmacother. 2023 Sep 14;167:115470. doi: 10.1016/j.biopha.2023.115470. Online ahead of print.ABSTRACTPolycystic ovarian syndrome (PCOS) is the most common endocrine and metabolic disorder in women of childbearing age, with ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology (PCOM) as the clinical features. Androgen excess, insulin resistance, obesity, adipose tissue dysfunction, ovulatory dysfunction, and gut microbiota dysbiosis are the main pathological features and pathogenesis of PCOS and are related to systemic chronic low-grade inflammation and chronic ovarian tissue inflammation in PC...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 16, 2023 Category: Drugs & Pharmacology Authors: Yuanyuan Feng Zhijing Tang Wei Zhang Source Type: research
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Biomed Pharmacother. 2023 Sep 14;167:115514. doi: 10.1016/j.biopha.2023.115514. Online ahead of print.ABSTRACTProgrammed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed on the surface of immune cells. As a receptor and immune checkpoint, PD-1 can bind to programmed death ligand-1/programmed death ligand-2 (PD-L1/PD-L2) in tumor cells, leading to tumor immune evasion. Anti-PD-1 and anti-PD-L1 are important components in tumor immune therapy. PD-1 is also expressed as an intrinsic variant (iPD-1) in cancer cells where it plays important roles in malignant progression...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 16, 2023 Category: Drugs & Pharmacology Authors: Muhua Chen Lei Bie Jieer Ying Source Type: research
Progress in the treatment of drug-loaded nanomaterials in renal cell carcinoma
This article reviews the use of nanomaterials, such as liposomes, polymeric nanoparticles, nanocomposites, carbon nanomaterials, nanobubbles, nanomicelles, and mesoporous silica nanoparticles, for RCC treatment, and discusses their advantages and disadvantages.PMID:37716114 | DOI:10.1016/j.biopha.2023.115444
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 16, 2023 Category: Drugs & Pharmacology Authors: Jianyang Li Kunzhe Wu Jinmei Zhang Huan Gao Xiaohua Xu Source Type: research
Current progress in engineered and nano-engineered mesenchymal stem cells for cancer: From mechanisms to therapy
Biomed Pharmacother. 2023 Sep 14;167:115505. doi: 10.1016/j.biopha.2023.115505. Online ahead of print.ABSTRACTMesenchymal stem cells (MSCs), as self-renewing multipotent stromal cells, have been considered promising agents for cancer treatment. A large number of studies have demonstrated the valuable properties of MSC-based treatment, such as low immunogenicity and intrinsic tumor-trophic migratory properties. To enhance the potency of MSCs for therapeutic purposes, equipping MSCs with targeted delivery functions using genetic engineering is highly beneficial. Genetically engineered MSCs can express tumor suppressor agents...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 16, 2023 Category: Drugs & Pharmacology Authors: Forough Shams Bahareh Pourjabbar Nader Hashemi Navid Farahmandian Ali Golchin Ghader Nuoroozi Azam Rahimpour Source Type: research
